| P2093 | author name string | Donald B Kohn | |
| | Caroline Y Kuo | |
| P2860 | cites work | Efficacy of gene therapy for X-linked severe combined immunodeficiency | Q28288838 |
| | Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 | Q28290118 |
| | Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils | Q33387329 |
| | Stem-cell gene therapy for the Wiskott-Aldrich syndrome | Q33392766 |
| | Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study | Q33395718 |
| | Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity | Q33413888 |
| | Transplantation outcomes for severe combined immunodeficiency, 2000-2009. | Q34279715 |
| | Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. | Q34356904 |
| | Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency | Q34454454 |
| | A modified γ-retrovirus vector for X-linked severe combined immunodeficiency | Q34763502 |
| | Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. | Q34977294 |
| | Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. | Q35212333 |
| | Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy | Q35916190 |
| | The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies | Q36319931 |
| | Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. | Q36370817 |
| | Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction | Q36370822 |
| | Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome | Q37089728 |
| | How I treat ADA deficiency | Q37398309 |
| | Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification | Q38468273 |
| | Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). | Q40395546 |
| | False-positive HIV PCR test following ex vivo lentiviral gene transfer treatment of X-linked severe combined immunodeficiency vector | Q42552682 |
| | The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency | Q42833078 |
| | Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. | Q44033105 |
| | Gene therapy: is IL2RG oncogenic in T-cell development? | Q45862650 |
| | T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. | Q45866838 |
| | Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans | Q45874932 |
| | Bone marrow gene transfer in three patients with adenosine deaminase deficiency. | Q45879021 |
| | Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector | Q45880148 |
| | Gene therapy for immunodeficiency due to adenosine deaminase deficiency. | Q45882856 |
| | Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency | Q45884771 |
| | Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? | Q53067119 |
| | Wiskott-Aldrich syndrome | Q80104437 |
| | Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling | Q83392308 |
| P433 | issue | 5 | |
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 39 | |
| P577 | publication date | 2016-05-01 | |
| P1433 | published in | Current Allergy and Asthma Reports | Q2246111 |
| P1476 | title | Gene Therapy for the Treatment of Primary Immune Deficiencies | |
| P478 | volume | 16 | |